The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.
Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL).
Age 18-65.
ECOG score: 0-2.
No history of previous chemotherapy or target therapy.
AML transformed with chronic myelogenous leukemia.
Acute promyelocytic leukemia (type M3).
Patients with a second malignancy requiring treatment.
Patients with uncontrolled active infection.